160 related articles for article (PubMed ID: 25040015)
1. Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis.
Davidai G; Cotton D; Gorelick P; Bath PM; Lipton RB; Sacco R; Diener HC
Eur J Neurol; 2014 Oct; 21(10):1311-7. PubMed ID: 25040015
[TBL] [Abstract][Full Text] [Related]
2. The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Uchiyama S; Ikeda Y; Urano Y; Horie Y; Yamaguchi T
Cerebrovasc Dis; 2011; 31(6):601-13. PubMed ID: 21502757
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
4. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
5. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Sacco RL; Diener HC; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; Vandermaelen C; Voigt T; Weber M; Yoon BW;
N Engl J Med; 2008 Sep; 359(12):1238-51. PubMed ID: 18753638
[TBL] [Abstract][Full Text] [Related]
6. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
Bath PM; Cotton D; Martin RH; Palesch Y; Yusuf S; Sacco R; Diener HC; Estol C; Roberts R;
Stroke; 2010 Apr; 41(4):732-8. PubMed ID: 20181679
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.
Offman E; Schobelock MJ; Brickl R; VanderMaelen CP; Ehrlich J; Eisert W
Am J Cardiovasc Drugs; 2013 Apr; 13(2):113-20. PubMed ID: 23532686
[TBL] [Abstract][Full Text] [Related]
9. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.
Diener HC; Sacco RL; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; VanderMaelen C; Voigt T; Weber M; Yoon BW;
Lancet Neurol; 2008 Oct; 7(10):875-84. PubMed ID: 18757238
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Malloy RJ; Kanaan AO; Silva MA; Donovan JL
Clin Ther; 2013 Oct; 35(10):1490-1500.e7. PubMed ID: 24139421
[TBL] [Abstract][Full Text] [Related]
11. Dose titration to reduce dipyridamole-related headache.
Chang YJ; Ryu SJ; Lee TH
Cerebrovasc Dis; 2006; 22(4):258-62. PubMed ID: 16788299
[TBL] [Abstract][Full Text] [Related]
12. Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group.
Sivenius J; Cunha L; Diener HC; Forbes C; Laakso M; Lowenthal A; Smets P; Riekkinen P
Acta Neurol Scand; 1999 Jan; 99(1):54-60. PubMed ID: 9925239
[TBL] [Abstract][Full Text] [Related]
13. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study.
Weimar C; Cotton D; Sha N; Sacco RL; Bath PM; Weber R; Diener HC
Cerebrovasc Dis; 2013; 35(6):538-43. PubMed ID: 23816610
[TBL] [Abstract][Full Text] [Related]
16. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
17. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
18. [Does early high dosage dipyridamole in prevention of secondary stroke induce cardiac events?].
Diener HC; Darius H; Bertrand-Hardy JM; Humphreys M
Z Kardiol; 2001 May; 90(5):348-51. PubMed ID: 11452896
[TBL] [Abstract][Full Text] [Related]
19. Review and management of side effects associated with antiplatelet therapy for prevention of recurrent cerebrovascular events.
Guthrie R
Adv Ther; 2011 Jun; 28(6):473-82. PubMed ID: 21547541
[TBL] [Abstract][Full Text] [Related]
20. Titrated initiation of acetylsalicylic acid-dipyridamole therapy reduces adverse effects and improves tolerance in patients with stroke.
Douen AG; Medic S; Sabih M; Pageau N; Shuaib A
J Stroke Cerebrovasc Dis; 2008; 17(6):356-9. PubMed ID: 18984426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
